Response to letter to the editor from Zhang et al: "Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer" Correspondence

  

Authors:	Konda, B.; Sherman, E. J.; Massarelli, E.; Nieva, J.; Muzaffar, J.; Morris, J. C. 3rd; Ryder, M.; Ho, A. L.; Agulnik, M.; Wei, L.; Handley, D.; Moses, C.; Jacob, R.; Wright, J.; Streicher, H.; Carson, W.; Shah, M. H.
Title:	Response to letter to the editor from Zhang et al: "Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer"
Keywords:	follow up; letter; ipilimumab; quality of life; cancer therapy; thyroid cancer; sample size; cabozantinib; nivolumab; human
Journal Title:	Journal of Clinical Endocrinology and Metabolism
Volume:	110
Issue:	7
ISSN:	0021-972X
Publisher:	Oxford University Press
Date Published:	2025-07-01
Start Page:	e2425
End Page:	e2426
Language:	English
DOI:	10.1210/clinem/dgaf221
PUBMED:	40184489
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105009362653&doi=10.1210%2fclinem%2fdgaf221&partnerID=40&md5=5cd84eb103917bd7ff7641318a6ef57a
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/227282